Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial.

Kohei Kaku,Masakazu Haneda,Hiroyuki Sakamaki,Atsutaka Yasui,Tatsunori Murata,Anastasia Ustyugova,Rina Chin,Tetsuaki Hirase, Tsunehisa Shibahara,Naoyuki Hayashi,Anuraag Kansal,Stefan Kaspers,Tomoo Okamura

Clinical Therapeutics（2019）

引用 20|浏览22

暂无评分

摘要

Based on the Asian subpopulation in the EMPA-REG OUTCOME trial, our results suggest that empagliflozin added to SoC is highly cost-effective compared with SoC alone in Japan.

查看译文

关键词

cost-effectiveness analysis,diabetes,EMPA-REG OUTCOME trial,empagliflozin,SGLT2 inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要